<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872311</url>
  </required_header>
  <id_info>
    <org_study_id>MCL10416</org_study_id>
    <nct_id>NCT02872311</nct_id>
  </id_info>
  <brief_title>Open-Label Influenza Vaccine Evaluation</brief_title>
  <acronym>OLIVE</acronym>
  <official_title>Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshfield Clinic Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Marshfield Clinic Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the
      immune response to consecutive influenza vaccination across 2 seasons. Participants will be
      randomized to receive 1 of 3 licensed and recommended vaccines in the first year; 2 arms will
      receive the same vaccination in the second year and the third arm will be randomized again to
      1 of 3 licensed vaccines. All participants will have pre and post-vaccination serum blood
      draws for a total of 6 draws over 18 months.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean Hemagglutination inhibition (HI) Antibody Titers</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric mean Hemagglutination inhibition (HI) antibody titers at each time point will be compared by arm</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>High Dose Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine+HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine +Adj</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine+Recomb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High Dose Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
    <arm_group_label>High Dose Influenza Vaccine</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine+HD</arm_group_label>
    <other_name>Fluzone HD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
    <arm_group_label>Adjuvanted Influenza Vaccine</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine +Adj</arm_group_label>
    <other_name>FluAd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Dose Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
    <arm_group_label>Standard Dose Influenza Vaccine+HD</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine +Adj</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine+Recomb</arm_group_label>
    <other_name>Fluvirin Standard Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved FluBlok vaccine to be administered to study participants</description>
    <arm_group_label>Standard Dose Influenza Vaccine+Recomb</arm_group_label>
    <other_name>FluBlok</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65-74 years at the time of study enrollment and are ambulatory and live in
             selected Wisconsin community or surrounding communities.

          -  Willing and able to give informed consent prior to study enrollment

          -  Able to comply with study requirements.

        Exclusion Criteria:

          -  Prior receipt of 2016-17 influenza vaccine

          -  Current participation in another clinical trial

          -  Presence of a contraindication to influenza vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marshfield Clinic Research Foundation</investigator_affiliation>
    <investigator_full_name>Huong McLean, PhD</investigator_full_name>
    <investigator_title>Associate Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Influenza</keyword>
  <keyword>High Dose</keyword>
  <keyword>Adjuvanted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

